20-Year Follow-up Study on Early Treatment and Relapse Effects in First Episode Psychosis
Led by The University of Hong Kong · Updated on 2026-06-26
178
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research investigates long-term clinical, cognitive, and functional outcomes in individuals diagnosed with schizophrenia or related psychotic disorders, focusing on the effects of early treatment choices and relapse patterns over 20 years. It aims to understand how early medication decisions and episodes of relapse influence these outcomes, and to explore factors leading to medication discontinuation and poor prognosis after first-episode psychosis.
The study involves a one-time face-to-face assessment of participants originally enrolled in a randomized controlled trial comparing antipsychotic maintenance versus discontinuation. Participants will undergo structured clinical interviews, cognitive testing, and psychosocial evaluations. Retrospective data from medical records on relapses, medication use, hospitalizations, and laboratory results will also be collected to analyze long-term trajectories and subgroup differences.
Participants contribute by attending a single interview guided by a research assistant, answering questions about their background, symptoms, functioning, cognition, and psychological health. Researchers will measure long-term clinical outcomes, cognitive abilities, symptom severity, medication adherence, and quality of life. Data confidentiality and ethical standards are maintained throughout the study, which spans up to 20 years from original enrollment.
CONDITIONS
Brief Title
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
Research Team
L
Lai Ming Christy Hui, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with schizophrenia or related non-affective psychosis (schizophreniform, schizoaffective, brief psychotic disorder, or unspecified psychosis) as per DSM-IV
Aged 18 to 65 years at the time of original enrollment
Treated with antipsychotic drugs for at least 12 months
No history of relapse or exacerbation or asymptomatic (free of positive psychosis symptoms) at study entry
You will not qualify if you...
Diagnosis of drug-induced psychosis
Current treatment with clozapine, mood stabilizers (lithium, valproate, carbamazepine), or depot medication
High risk of suicide or violence
Unable to provide informed consent at recruitment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
One-Time Assessment
Duration - One day
Participants attend a single face-to-face interview where they answer questions about their background, clinical symptoms, daily functioning, cognitive abilities, and psychological well-being. Retrospective medical record reviews provide additional information on relapses, medication use, and hospitalizations.
1 visit (in-person)
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
52-Week Open Label Study to Assess Safety and Tolerability of LB-102 in Adults with Stable Schizophrenia
20-Year Follow-up Study on Early Treatment and Relapse Effects in First Episode Psychosis
Study Comparing Two Formulations of Paliperidone Palmitate Injection 3M in Chinese Adults with Schizophrenia
Randomized, Open-label, Multicenter, Multiple-dose Bioequivalence Study
A Phase 2 Study to Assess Safety and Effectiveness of Different Olanzapine Dosing Schedules in Adults with Schizophrenia
Long-term Study of SEP-363856 Tablets for Adults with Schizophrenia to Evaluate Safety and Tolerability
Long-Term Study of ML-007C-MA Treatment in Adults with Schizophrenia
Evaluating Safety, Tolerability, and Effectiveness Over 52 Weeks
Phase 1 Study of LY03020 Oral Tablets to Assess Safety, Tolerability, and Pharmacokinetics in Chinese Adults with Stable Schizophrenia or Healthy Volunteers
Phase 2 Study Evaluating Brenipatide with Standard Care for Schizophrenia Treatment in Adults Aged 18 to 55
Evaluating Safety and Effects of Oral LTX-001 in Adults with Recent Worsening of Schizophrenia Symptoms
Evaluation of Safety, Tolerability, and Feasibility of Aticaprant as Add-On Treatment for Adults with Schizophrenia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.
Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
Christy L M Hui, William G Honer, Edwin H M Lee...